Non-Clear Cell Renal Carcinomas: About 23 Cases Experience of the Medical Oncology Department of the Hassan II Hospital in Fez, Morocco — Oak Academic Publishing
Research ArticleOpen AccessGoogle Scholar indexed
Non-Clear Cell Renal Carcinomas: About 23 Cases Experience of the Medical Oncology Department of the Hassan II Hospital in Fez, Morocco
Department of Medical Oncology, Hassan II University Hospital, Fes, Morocco
,
Department of Medical Oncology, Hassan II University Hospital, Fes, Morocco
,
Department of Medical Oncology, Hassan II University Hospital, Fes, Morocco
,
Department of Medical Oncology, Hassan II University Hospital, Fes, Morocco
,
Department of Medical Oncology, Hassan II University Hospital, Fes, Morocco
,
Department of Medical Oncology, Hassan II University Hospital, Fes, Morocco
,
Department of Medical Oncology, Hassan II University Hospital, Fes, Morocco
,
Department of Medical Oncology, Hassan II University Hospital, Fes, Morocco
,
Department of Medical Oncology, Hassan II University Hospital, Fes, Morocco
1 Department of Medical Oncology, Hassan II University Hospital, Fes, Morocco
2 Department of Medical Oncology, Hassan II University Hospital, Fes, Morocco
3 Department of Medical Oncology, Hassan II University Hospital, Fes, Morocco
4 Department of Medical Oncology, Hassan II University Hospital, Fes, Morocco
5 Department of Medical Oncology, Hassan II University Hospital, Fes, Morocco
6 Department of Medical Oncology, Hassan II University Hospital, Fes, Morocco
7 Department of Medical Oncology, Hassan II University Hospital, Fes, Morocco
8 Department of Medical Oncology, Hassan II University Hospital, Fes, Morocco
9 Department of Medical Oncology, Hassan II University Hospital, Fes, Morocco
Background: Non-clear cell renal cell carcinomas represent a very rare and heterogeneous variety of kidney cancer. The aim of this study is to describe the main epidemiological, clinical, paraclinical, histological and therapeutic characteristics of these cancers. Methods: A descriptive retrospective study was conducted in the Medical Oncology Department of the Hassan II Hospital in Fez, collecting 23 patients with these tumors during the period from January 2008 to January 2020. The statistical analysis is made by the SPSS software version 23. Survival was calculated by the Kaplan-Meier method. Results: The average age of the patients was 57.4 years. The sex ratio M/F was 1.3. The main risk factor was smoking (n = 10). The most common symptom was low back pain (n = 23). 17 patients were metastatic, while 6 patients had localized disease. The most common histological type was papillary carcinoma (n = 12). Patients with localized disease have undergone an extended total nephrectomy. After a median follow-up of 145 months, the median of recurrence-free survival was 48 months and that of overall survival was 150 months. In a metastatic situation, 16 patients had received systemic treatment, of which 13 patients had received sunitinib, 2 patients pazaopanib and only one patient received everolimus. After a median follow-up of 20 months, the median of progression-free survival was 5 months and that of overall survival was 9 months. Conclusion: At the present time, there is no therapeutic standard for the management of patients with these tumors. Surgery for people with localized or locally advanced disease remains the initial and most important approach. For patients with advanced disease, a clinical trial should be considered.
Ferlay, J., Soerjomataram, I., Dikshit, R., et al. (2015) Cancer Incidence and Mortality Worldwide: Sources, Methods and Major Patterns in GLOBOCAN 2012. International Journal of Cancer, 136, E359-E386. https://doi.org/10.1002/ijc.29210
Cohen, H.T. and McGovern, F.J. (2005) Renal-Cell Carcinoma. The New England Journal of Medicine, 353, 2477-2490. https://doi.org/10.1056/NEJMra043172
Reuter, V.E. (2006) The Pathology of Renal Epithelial Neoplasms. Seminars in Oncology, 33, 534-543. https://doi.org/10.1053/j.seminoncol.2006.06.009
Pal, S.K. and Choueiri, T.K. (2014) Systemic Therapies for Metastatic Renal Cell Carcinoma of Variant Histology. In: Tannir, N.M., Ed., Renal Cell Carcinoma, Oxford American Oncology Library, New York, 109-116.
Mejean, A., Andre, M., Doublet, J.D., et al. (2004) Tumeurs du rein. Progrès en Urologie, 14, 999-1035.
Kovacs, G., Akhtar, M., Beckwith, B.J., et al. (1997) The Heidelberg Classification of Renal Cell Tumours. The Journal of Pathology, 183, 131-310. https://doi.org/10.1002/(SICI)1096-9896(199710)183:2 3.0.CO;2-G
Delahunt, B. and Eble, J.N. (1997) Papillary Renal Cell Carcinoma: A Clinicopathologic and Immunohistochemical Study of 105 Tumors. Modern Pathology, 10, 537-544.
Yang, X.J., Tan, M.H., Kim, H.L., et al. (2005) A Molecular Classification of Papillary Renal Cell Carcinoma. Cancer Research, 65, 5628-5637. https://doi.org/10.1158/0008-5472.CAN-05-0533
Gillett, M.D., Cheville, J.C., Karnes, R.J., et al. (2005) Comparison of Presentation and Outcome for Patients 18 to 40 and 60 to 70 Years Old with Solid Renal Masses. Journal of Urology, 173, 1893-1896. https://doi.org/10.1097/01.ju.0000158157.57981.80
Purdue, M.P., Moore, L.E., Merino, M.J., et al. (2013) An Investigation of Risk Factors for Renal Cell Carcinoma by Histologic Subtype in Two Case-Control Studies. International Journal of Cancer, 132, 2640-2647. https://doi.org/10.1002/ijc.27934
Cheville, J.C., Lohse, C.M., Zincke, H., Weaver, A.L. and Blute, M.L. (2003) Comparisons of Outcome and Prognostic Features among Histologic Subtypes of Renal Cell Carcinoma. The American Journal of Surgical Pathology, 27, 612-624. https://doi.org/10.1097/00000478-200305000-00005
Kwon, K.A., Oh, S.Y., Kim, H.Y., et al. (2014) Clinical Features and Treatment of Collecting Duct Carcinoma of the Kidney from the Korean Cancer Study Group Genitourinary and Gynecology Cancer Committee. Cancer Research and Treatment, 46, 141-147. https://doi.org/10.4143/crt.2014.46.2.141
Sidhar, S.K., Clark, J., Gill, S., et al. (1996) The t(X;1)(p11.2;q21.2) Translocation in Papillary Renal Cell Carcinoma Fuses a Novel Gene PRCC to the TFE3 Transcription Factor Gene. Human Molecular Genetics, 5, 1333-1338. https://doi.org/10.1093/hmg/5.9.1333
Zisman, A., Chao, D.H., Pantuck, A.J., et al. (2002) Unclassified Renal Cell Carcinoma: Clinical Features and Prognostic Impact of a New Histological Subtype. Journal of Urology, 168, 950-955. https://doi.org/10.1016/S0022-5347(05)64549-1
Moch, H., Cubilla, A.L., Humphrey, P.A., Reuter, V.E. and Ulbright, T.M. (2016) The 2016 WHO Classification of Tumours of the Urinary System and Male Genital Organs Part A: Renal, Penile, and Testicular Tumours. European Urology, 70, 93-105. https://doi.org/10.1016/j.eururo.2016.02.029
Comperat, E.V., Vasiliu, V., Ferlicot, S., Camparo, P., Sibony, M. and Vieillefond, A. (2005) Les cancers du rein: Nouvelle classification. Annales de Pathologie, 25, 117-133. https://doi.org/10.1016/S0242-6498(05)86175-9
Motzer, R.J., Agarwal, N., Beard, C., et al. (2011) NCCN Clinical Practice Guidelines in Oncology for Kidney Cancer. Journal of the National Comprehensive Cancer Network, 9, 960-977. https://doi.org/10.6004/jnccn.2011.0082
Armstrong, A.J., Halabi, S., Eisen, T., et al. (2016) Everolimus versus Sunitinib for Patients with Metastatic Non-Clear Cell Renal Cell Carcinoma (ASPEN): A Multicentre, Open-Label, Randomised Phase 2 Trial. The Lancet Oncology, 17, 378-388. https://doi.org/10.1016/S1470-2045(15)00515-X
Knox, J.J., et al. (2017) Final Overall Survival Analysis for the Phase II RECORD-3 Study of First-Line Everolimus Followed by Sunitinib versus First-Line Sunitinib Followed by Everolimus in Metastatic RCC. Annals of Oncology, 28, 1339-1345. https://doi.org/10.1093/annonc/mdx075
Tannir, N.M., et al. (2016) Everolimus versus Sunitinib Prospective Evaluation in Metastatic Non-Clear Cell Renal Cell Carcinoma (ESPN): A Randomized Multicenter Phase 2 Trial. European Urology, 69, 866-874. https://doi.org/10.1016/j.eururo.2015.10.049
Hudes, G., Carducci, M., et al. (2007) Temsirolimus, Interferon Alfa, or Both for Advanced Renal-Cell Carcinoma. The New England Journal of Medicine, 356, 2271-2281. https://doi.org/10.1056/NEJMoa066838
Twardowski, P.W., et al. (2017) Parallel (Randomized) Phase II Evaluation of Tivantinib (ARQ197) and Tivantinib in Combination with Erlotinib in Papillary Renal Cell Carcinoma: SWOG S1107. Kidney Cancer, 1, 123-132. https://doi.org/10.3233/KCA-170018
Flanigan, R.C., Salmon, S.E., Blumenstein, B.A., et al. (2001) Nephrectomy Followed by Interferon alfa-2b Compared with Interferon alfa-2b Alone for Metastatic Renal-Cell Cancer. The New England Journal of Medicine, 345, 1655-1659. https://doi.org/10.1056/NEJMoa003013
Mickisch, G.H., Garin, A., van Poppel, H., de Prijck, L., Sylvester, R., European Organisation for Research and Treatment of Cancer (EORTC) Genitourinary Group, et al. (2001) Radical Nephrectomy plus Interferon-Alfa-Based Immunotherapy Compared with Interferon Alfa Alone in Metastatic Renal-Cell Carcinoma: A Randomised Trial. The Lancet, 358, 966-970. https://doi.org/10.1016/S0140-6736(01)06103-7
Aizer, A.A., Urun, Y., McKay, R.R., Kibel, A., Nguyen, P.L. and Choueiri, T.K. (2013) Cytoreductive Nephrectomy in Patients with Metastatic Non-Clear Cell Renal Cell Carcinoma. BJU International, 113, 67-74. https://doi.org/10.1111/bju.12442